Serametrix provides effective immune monitoring of cancer patients samples to support clinical trials for novel combination and immune-based therapies.
Latest News
Caprion Biosciences and HistoGeneX Unite Businesses to Create Global Leader in Immune Monitoring and Biomarker Development
Partnership Facilitated by Major Investment from Arsenal Capital Partners NEW YORK, July 31, 2019 – Caprion Biosciences (“Caprion”) and HistoGeneX announced today they have agreed to combine their respective businesses. The new partnership creates a global leader in...
Caprion Biosciences Expands its Global Biomarker and Immune Monitoring Franchise by Acquiring Serametrix Corporation
MONTREAL, QUEBEC (April 30, 2019) / CNW Telbec / Caprion Biosciences announced today that the company acquired Serametrix Corporation, a specialized provider of immune monitoring services headquartered in Carlsbad, California. Caprion plans to leverage the proprietary...
©2019 Serametrix l US: +1-760-652-4060 l Europe: +44 (0)20 8973 3853 | info@serametrix.com